Methotrexate drug sales will expand through 2036, with psoriasis holding 15% of the indication segment in 2026. The market was valued at USD 655.5 million in 2025 and is expected to be worth USD 1181.27 million by 2036, creating an incremental opportunity of USD 489.72 million between 2026 and 2036.